Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Current Deferred Revenue (2016 - 2025)

Sangamo Therapeutics (SGMO) has disclosed Current Deferred Revenue for 16 consecutive years, with $899000.0 as the latest value for Q4 2025.

  • For Q4 2025, Current Deferred Revenue fell 88.1% year-over-year to $899000.0; the TTM value through Dec 2025 reached $899000.0, down 88.1%, while the annual FY2025 figure was $899000.0, 88.1% down from the prior year.
  • Current Deferred Revenue hit $899000.0 in Q4 2025 for Sangamo Therapeutics, down from $7.6 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $94.4 million in Q1 2021 and bottomed at $774000.0 in Q3 2024.
  • Average Current Deferred Revenue over 5 years is $41.0 million, with a median of $9.6 million recorded in 2023.
  • Year-over-year, Current Deferred Revenue crashed 97.93% in 2023 and then surged 876.23% in 2025.
  • Sangamo Therapeutics' Current Deferred Revenue stood at $85.7 million in 2021, then tumbled by 39.59% to $51.8 million in 2022, then crashed by 97.13% to $1.5 million in 2023, then soared by 408.82% to $7.6 million in 2024, then crashed by 88.1% to $899000.0 in 2025.
  • According to Business Quant data, Current Deferred Revenue over the past three periods came in at $899000.0, $7.6 million, and $7.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.